Sectors & Industries HealthcareBiotechnology
Best Biotech Stocks to Buy Now (2025)
Top biotech stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best biotech stocks to buy now. Learn More.

Industry: Biotechnology

Overview Zen Rating Price Value Growth Financials

Momentum Sentiment Forecast Dividends Due Diligence

Biotech is Zen Rated F and is the 137th ranked industry out of 145 stock market industries

Ticker	Company	Market Cap	ROE	ROA	ROCE	ROIC	D/E	Current Ratio	Gross Margin	Profit Margin	Operating Margin
GNPX	GENPREX INC	$6.88M	-522.10%	-314.50%	-1,303.03%	-4,612.40%	1.55	0.83	N/A	N/A	N/A
ERNA	ETERNA THERAPEUTICS INC	$11.28M	N/A	-163.30%	-1,619.78%	-81.80%	2.10	0.80	83.50%	-7,655.50%	-6,487.46%
CAMP	CAMP4 THERAPEUTICS CORP	$41.33M	N/A	-77.70%	-75.38%	-333.10%	0.24	6.92	100.00%	-7,943.40%	-7,943.40%
CARM	CARISMA THERAPEUTICS INC	$9.44M	N/A	-117.60%	-419.89%	-942.70%	-2.09	1.48	100.00%	-308.10%	-308.05%
BLRX	BIOLINERX LTD	$14.38M	-75.30%	-17.70%	-0.43%	-1.70%	1.89	1.76	68.00%	-31.90%	-0.35%
SILO	SILO PHARMA INC	$5.16M	-76.20%	-56.80%	-76.23%	-187.00%	0.47	4.29	91.90%	-6,092.60%	-6,085.54%
SLGL	SOL-GEL TECHNOLOGIES LTD	$21.78M	-27.20%	-22.50%	-26.26%	-41.70%	0.24	5.81	100.00%	-81.70%	-81.75%
BCAB	BIOATLA INC	$25.75M	-235.90%	-102.40%	-184.19%	690.60%	2.68	3.52	100.00%	-634.30%	-634.33%
BHST	BIOHARVEST SCIENCES INC	$113.50M	-574.70%	-56.90%	-65.06%	-37.70%	17.80	0.55	55.40%	-51.30%	-27.75%
BCLI	BRAINSTORM CELL THERAPEUTICS INC	$6.36M	N/A	-360.70%	161.57%	251.60%	-1.24	0.04	N/A	N/A	N/A
IMMX	IMMIX BIOPHARMA INC	$51.84M	-104.70%	-77.70%	-151.27%	-59,867.00%	0.73	2.33	N/A	N/A	N/A
CLRB	CELLECTAR BIOSCIENCES INC	$14.28M	-262.20%	-132.00%	-276.73%	375.30%	0.69	2.58	N/A	N/A	N/A
LVTX	LAVA THERAPEUTICS NV	$34.46M	-65.10%	-28.30%	-38.15%	-53.60%	1.91	4.40	100.00%	-209.60%	-200.04%
AVTE	AEROVATE THERAPEUTICS INC	$77.68M	-81.40%	-71.40%	-90.94%	-115.70%	0.05	20.93	N/A	N/A	N/A
AZTR	AZITRA INC	$4.76M	-181.10%	-132.40%	-149.53%	-475.80%	0.29	3.80	100.00%	-119,566.60%	-119,284.01%
KTTA	PASITHEA THERAPEUTICS CORP	$4.68M	-81.00%	-74.40%	-93.04%	2,379.10%	0.09	6.58	N/A	N/A	N/A
CALC	CALCIMEDICA INC	$20.22M	-100.50%	-65.10%	-85.04%	-138.30%	0.37	5.34	N/A	N/A	N/A
BYSI	BEYONDSPRING INC	$64.51M	N/A	-37.60%	-47.32%	-91.60%	-1.48	2.60	N/A	N/A	N/A
BCDA	BIOCARDIA INC	$9.22M	N/A	-204.30%	-566.36%	1,041.40%	3.45	1.13	100.00%	-13,700.00%	-13,700.00%
MOLN	MOLECULAR PARTNERS AG	$154.79M	-35.80%	-32.30%	-36.55%	-58.10%	0.12	14.31	100.00%	-1,087.40%	-1,086.58%
ARTL	ARTELO BIOSCIENCES INC	$3.41M	-150.90%	-128.80%	-335.82%	-396.20%	0.64	1.44	N/A	N/A	N/A
SRZN	SURROZEN INC	$32.90M	-1,241.20%	-142.60%	-154.46%	-743.00%	-3.27	5.32	100.00%	-596.60%	-596.56%
APM	APTORUM GROUP LTD	$5.31M	0.10%	0.10%	0.70%	0.70%	0.20	1.17	N/A	N/A	N/A
APLT	APPLIED THERAPEUTICS INC	$56.49M	-208.60%	-89.50%	-177.83%	179.90%	0.52	3.06	100.00%	-23,214.10%	-23,214.07%
ADIL	ADIAL PHARMACEUTICALS INC	$4.50M	-259.40%	-225.70%	-324.41%	-1,720.70%	0.24	4.16	N/A	N/A	N/A
ARMP	ARMATA PHARMACEUTICALS INC	$51.38M	N/A	-18.30%	-21.40%	-7.00%	-2.80	0.23	100.00%	-365.60%	-157.98%
ALZN	ALZAMEND NEURO INC	$4.49M	-504.20%	-149.10%	-121.98%	316.10%	0.21	5.44	N/A	N/A	N/A
MNOV	MEDICINOVA INC	$76.51M	-19.70%	-18.60%	-20.87%	-294.20%	0.06	13.88	N/A	N/A	N/A
APRE	APREA THERAPEUTICS INC	$8.73M	-54.10%	-45.50%	-69.10%	609.80%	0.24	7.02	100.00%	-862.40%	-948.23%
PBM	PSYENCE BIOMEDICAL LTD	$2.15M	N/A	-583.50%	465.76%	5,423.00%	-1.10	0.09	N/A	N/A	N/A
ALLK	ALLAKOS INC	$29.50M	-136.40%	-83.50%	-155.13%	-106.00%	0.23	4.81	N/A	N/A	N/A
PPBT	PURPLE BIOTECH LTD	$139.62M	23.60%	19.60%	23.37%	-189.50%	0.13	2.23	N/A	N/A	N/A
ADAG	ADAGENE INC	$66.90M	-55.20%	-32.60%	-63.80%	343.60%	0.77	2.30	100.00%	-32,386.40%	-31,578.03%
TTNP	TITAN PHARMACEUTICALS INC	$3.38M	-119.50%	-107.40%	-192.87%	2,704.60%	0.20	6.05	N/A	N/A	N/A
XTLB	XTL BIOPHARMACEUTICALS LTD	$7.79M	-57.30%	-53.90%	N/A	-151.20%	0.09	N/A	N/A	N/A	N/A
PHGE	BIOMX INC	$15.25M	-88.70%	-28.00%	-48.16%	-48.70%	0.79	2.48	N/A	N/A	N/A
NBTX	NANOBIOTIX SA	$149.39M	N/A	-84.50%	-713.70%	-418.40%	-2.03	1.04	100.00%	947.50%	841.93%
TOVX	THERIVA BIOLOGICS INC	$3.95M	-101.60%	-61.60%	-92.39%	-135.60%	0.85	2.15	N/A	N/A	N/A
TNYA	TENAYA THERAPEUTICS INC	$43.00M	-89.30%	-73.00%	-106.89%	-95.50%	0.29	4.22	N/A	N/A	N/A
AEON	AEON BIOPHARMA INC	$4.53M	-58.50%	1,055.90%	-381.62%	2,113.50%	-1.11	0.11	N/A	N/A	N/A
OVID	OVID THERAPEUTICS INC	$24.66M	-33.90%	-23.80%	-32.38%	-27.60%	0.35	5.32	100.00%	-4,670.10%	-4,670.14%
KLTO	KLOTHO NEUROSCIENCES INC	$4.90M	-1,691.40%	-232.70%	-478.89%	-2,583.80%	1.07	0.13	N/A	N/A	N/A
PYPD	POLYPID LTD	$26.50M	-1,038.70%	-143.00%	-223.53%	-272.10%	2.28	1.31	N/A	N/A	N/A
ONVO	ORGANOVO HOLDINGS INC	$2.97M	-346.30%	-187.50%	-1,364.72%	-567.00%	9.56	0.72	95.90%	-10,151.60%	-10,145.90%
PALI	PALISADE BIO INC	$3.17M	-169.30%	-126.30%	-188.72%	1,186.60%	0.45	3.24	N/A	N/A	N/A
OKYO	OKYO PHARMA LTD	$51.24M	N/A	N/A	143.30%	N/A	-1.39	0.28	N/A	N/A	N/A
KZIA	KAZIA THERAPEUTICS LTD	$2.42M	-2,634.30%	-107.80%	642.19%	376.90%	-3.16	0.24	100.00%	-1,079.30%	-1,090.25%
VANI	VIVANI MEDICAL INC	$62.21M	-106.20%	-50.40%	-66.02%	-66.00%	1.36	3.42	N/A	N/A	N/A
ASBP	ASPIRE BIOPHARMA HOLDINGS INC	$23.81M	N/A	-15.50%	78.62%	-15.80%	-1.10	0.09	N/A	N/A	N/A
TENX	TENAX THERAPEUTICS INC	$23.03M	-33.40%	-31.80%	-19.11%	1,811.50%	0.05	20.60	N/A	N/A	N/A
QNCX	QUINCE THERAPEUTICS INC	$54.12M	-115.80%	-42.50%	-52.93%	-88.60%	2.80	6.05	N/A	N/A	N/A
TCRT	ALAUNOS THERAPEUTICS INC	$4.21M	-140.10%	-110.00%	-226.81%	-471.10%	0.34	3.98	100.00%	-46,790.00%	-46,790.00%
THAR	THARIMMUNE INC	$2.53M	-270.00%	-186.80%	-931.74%	813.60%	1.85	1.54	N/A	N/A	N/A
VRCA	VERRICA PHARMACEUTICALS INC	$44.88M	N/A	-149.10%	-267.36%	-177.30%	-6.49	1.76	63.80%	-1,012.10%	-887.75%
IMNN	IMUNON INC	$12.84M	-301.80%	-154.80%	-377.60%	-786.70%	1.29	1.67	N/A	N/A	N/A
SPRO	SPERO THERAPEUTICS INC	$40.53M	-95.10%	-48.70%	-111.55%	-225.20%	1.40	2.19	100.00%	-142.90%	-142.91%
TSBX	TURNSTONE BIOLOGICS CORP	$8.10M	-131.90%	-105.00%	-221.67%	-199.10%	0.28	4.17	N/A	N/A	N/A
SNGX	SOLIGENIX INC	$6.85M	-231.50%	-88.50%	-215.87%	358.00%	1.18	1.82	0.00%	-6,925.10%	-7,447.09%
SYBX	SYNLOGIC INC	$13.61M	-169.40%	-95.10%	-183.15%	3,265.20%	0.56	2.80	100.00%	-291,987.50%	-291,925.00%
SER	SERINA THERAPEUTICS INC	$58.10M	N/A	-124.70%	-243.58%	-992.30%	9.70	2.40	100.00%	-19,894.60%	-18,955.36%
ZYBT	ZHENGYE BIOTECHNOLOGY HOLDING LTD	N/A	N/A	N/A	13.78%	N/A	0.59	1.37	61.40%	14.90%	22.77%

Biotech Stocks FAQ

What are the best biotech stocks to buy right now in Apr 2025?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best biotechnology stocks to buy right now are:

1. Protalix Biotherapeutics (NYSEMKT:PLX)

Protalix Biotherapeutics (NYSEMKT:PLX) is the #1 top biotech stock out of 661 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Protalix Biotherapeutics (NYSEMKT:PLX) is: Value: B, Growth: A, Momentum: B, Sentiment: A, Safety: C, Financials: B, and AI: C.

Protalix Biotherapeutics (NYSEMKT:PLX) has a Due Diligence Score of 23, which is -1 points lower than the biotech industry average of 24. Although this number is below the industry average, our proven quant model rates PLX as a "A".

PLX passed 7 out of 33 due diligence checks and has weak fundamentals. Protalix Biotherapeutics has seen its stock return 141.53% over the past year, overperforming other biotech stocks by 220 percentage points.

Protalix Biotherapeutics has an average 1 year price target of $15.00, an upside of 426.32% from Protalix Biotherapeutics's current stock price of $2.85.

Protalix Biotherapeutics stock has a consensus Buy recommendation according to Wall Street analysts. Of the 1 analyst covering Protalix Biotherapeutics, 0% have issued a Strong Buy rating, 100% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Aurinia Pharmaceuticals (NASDAQ:AUPH)

Aurinia Pharmaceuticals (NASDAQ:AUPH) is the #2 top biotech stock out of 661 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Aurinia Pharmaceuticals (NASDAQ:AUPH) is: Value: B, Growth: A, Momentum: C, Sentiment: A, Safety: C, Financials: B, and AI: C.

Aurinia Pharmaceuticals (NASDAQ:AUPH) has a Due Diligence Score of 57, which is 33 points higher than the biotech industry average of 24.

AUPH passed 19 out of 33 due diligence checks and has strong fundamentals. Aurinia Pharmaceuticals has seen its stock return 67.97% over the past year, overperforming other biotech stocks by 146 percentage points.

3. Catalyst Pharmaceuticals (NASDAQ:CPRX)

Catalyst Pharmaceuticals (NASDAQ:CPRX) is the #3 top biotech stock out of 661 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Catalyst Pharmaceuticals (NASDAQ:CPRX) is: Value: A, Growth: C, Momentum: C, Sentiment: A, Safety: D, Financials: A, and AI: B.

Catalyst Pharmaceuticals (NASDAQ:CPRX) has a Due Diligence Score of 76, which is 52 points higher than the biotech industry average of 24.

CPRX passed 25 out of 33 due diligence checks and has strong fundamentals. Catalyst Pharmaceuticals has seen its stock return 59.74% over the past year, overperforming other biotech stocks by 138 percentage points.

Catalyst Pharmaceuticals has an average 1 year price target of $33.20, an upside of 41.58% from Catalyst Pharmaceuticals's current stock price of $23.45.

Catalyst Pharmaceuticals stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 5 analysts covering Catalyst Pharmaceuticals, 60% have issued a Strong Buy rating, 40% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the biotech stocks with highest dividends?

Out of 5 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

1. Dominari Holdings (NASDAQ:DOMH)

Dominari Holdings (NASDAQ:DOMH) has an annual dividend yield of 6.68%, which is 5 percentage points higher than the biotech industry average of 1.9%.

Dominari Holdings's dividend payout ratio of -13.4% indicates that its high dividend yield might not be sustainable for the long-term.

2. Novo Nordisk (Ozempic) (NYSE:NVO)

Novo Nordisk (Ozempic) (NYSE:NVO) has an annual dividend yield of 2.6%, which is 1 percentage points higher than the biotech industry average of 1.9%. Novo Nordisk (Ozempic)'s dividend payout is not stable, having dropped more than 10% nine times in the last 10 years. Novo Nordisk (Ozempic)'s dividend has shown consistent growth over the last 10 years.

Novo Nordisk (Ozempic)'s dividend payout ratio of 45.5% indicates that its dividend yield is sustainable for the long-term.

3. Royalty Pharma (NASDAQ:RPRX)

Royalty Pharma (NASDAQ:RPRX) has an annual dividend yield of 1.34%, which is -1 percentage points lower than the biotech industry average of 1.9%. Royalty Pharma's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Royalty Pharma's dividend has shown consistent growth over the last 10 years.

Royalty Pharma's dividend payout ratio of 43.8% indicates that its dividend yield is sustainable for the long-term.

Why are biotech stocks down?

Biotech stocks were down -0.65% in the last day, and up 6% over the last week. Intensity Therapeutics was the among the top losers in the biotechnology industry, dropping -37.11% yesterday.

Intensity Therapeutics shares are trading lower after the company announced a $2.35 million public offering.

What are the most undervalued biotech stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued biotech stocks right now are:

1. Harmony Biosciences Holdings (NASDAQ:HRMY)

Harmony Biosciences Holdings (NASDAQ:HRMY) is the most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 71, which is 57 points higher than the biotech industry average of 14. It passed 5 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has gained 2.35% in the past year. It has overperformed other stocks in the biotech industry by 80 percentage points.

2. Puma Biotechnology (NASDAQ:PBYI)

Puma Biotechnology (NASDAQ:PBYI) is the second most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Puma Biotechnology has a valuation score of 43, which is 29 points higher than the biotech industry average of 14. It passed 3 out of 7 valuation due diligence checks.

Puma Biotechnology's stock has dropped -38.52% in the past year. It has overperformed other stocks in the biotech industry by 40 percentage points.

3. Jazz Pharmaceuticals (NASDAQ:JAZZ)

Jazz Pharmaceuticals (NASDAQ:JAZZ) is the third most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Jazz Pharmaceuticals has a valuation score of 71, which is 57 points higher than the biotech industry average of 14. It passed 5 out of 7 valuation due diligence checks.

Jazz Pharmaceuticals's stock has gained 3.14% in the past year. It has overperformed other stocks in the biotech industry by 81 percentage points.

Are biotech stocks a good buy now?

55.47% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 108.65% over the next year.

1.53% of biotech stocks have a Zen Rating of A (Strong Buy), 5.03% of biotech stocks are rated B (Buy), 41.79% are rated C (Hold), 35.67% are rated D (Sell), and 15.97% are rated F (Strong Sell).

What is the average p/e ratio of the biotechnology industry?

The average P/E ratio of the biotechnology industry is -157.91x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.